Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRCAP: ICS/LABA Intervention for COPD Exacerbation Under Severe Air Pollution
NCT03083067Completed
- Sponsor
- Peking University First Hospital
- Start
- Mar 2017
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of budesonide + formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Frequency of Acute Exacerbation of COPD per year at 3 years. Started Mar 2017; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03083067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083067.